<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162433</url>
  </required_header>
  <id_info>
    <org_study_id>14-019H</org_study_id>
    <nct_id>NCT02162433</nct_id>
  </id_info>
  <brief_title>The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation</brief_title>
  <official_title>Does Dexmedetomidine Decrease the Incidence of Untoward Airway Events After Deep or Awake Extubation in Patients Undergoing Adenotonsillectomy With or Without Myringotomy and Tube Placement?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the effect of dexmedetomidine on the perioperative
      respiratory complications in this patient population undergoing both awake and deep tracheal
      extubation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a prospective double-blinded randomized controlled trial. 336 pediatric patients
      presenting to Massachusetts Eye and Ear Infirmary (MEEI) for adenotonsillectomy who are
      eligible for the study based on inclusion and exclusion criteria will be recruited. A
      Clinical Pharmacy specialist, will be in charge of preparing the dexmedetomidine and placebo
      doses and will randomize the patients to four equally numbered groups. The anesthesiologist
      will receive the assignment for the extubation method in a sealed envelope from the Clinical
      Pharmacy specialist. Multiple parameters will be recorded in perioperative period to quantify
      perioperative adverse respiratory events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory Complications</measure>
    <time_frame>2 years</time_frame>
    <description>desaturation to less than 95% for more than 10 seconds;
breath holding;
complete or partial laryngospasm;
bronchospasm;
croup;
number of episodes of persistent cough (three or more consecutive coughs);
negative pressure pulmonary edema;
stridor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anesthesia/Surgery Side Effects</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of emergence agitation;
Incidence of postoperative nausea and vomiting (PONV);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Parameters</measure>
    <time_frame>2 years</time_frame>
    <description>Length of time from end of surgery to leaving the operating room;
The length of stay from admission to the PACU to discharge home;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour Postoperative follow-up Pain medication Requirements</measure>
    <time_frame>2 years</time_frame>
    <description>5) 24-hour postoperative pain control requirements assessed by the questionnaire given to parents at the time of discharge;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospital admission</measure>
    <time_frame>2 years</time_frame>
    <description>6) Any unplanned hospital admission due to perioperative respiratory adverse events.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Adenotonsillar Hypertrophy</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Tonsillitis</condition>
  <condition>Adenoiditis</condition>
  <arm_group>
    <arm_group_label>1. Awake extubation/dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Awake extubation receiving dexmedetomidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Awake extubation/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Awake extubation receiving placebo (normal saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.Deep extubation/dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep extubation receiving dexmedetomidine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Deep extubation/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Deep extubation receiving placebo (normal saline).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>to arms 2,4. Serves as the placebo.</description>
    <arm_group_label>2. Awake extubation/placebo</arm_group_label>
    <arm_group_label>4. Deep extubation/placebo</arm_group_label>
    <other_name>0.9% Sodium Chloride Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>to arms 1,3</description>
    <arm_group_label>1. Awake extubation/dexmedetomidine</arm_group_label>
    <arm_group_label>3.Deep extubation/dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 3 to 16 years of age undergoing adenotonsillectomy, with or without
             myringotomy or myringoplasty

          -  ASA 1 &amp; 2

        Exclusion Criteria:

          -  Known allergy or hypersensitivity reaction to dexmedetomidine

          -  Organ dysfunction (renal/hepatic failure or leukemia)

          -  Cardiac disease (congenital or acquired)

          -  Airway or thoracic malformation

          -  Cerebral palsy

          -  Hypotonia

          -  Need for premedication

          -  Current/recent upper respiratory infection (within four weeks prior to the surgery)

          -  Asthma

          -  Allergy or intolerance to clonidine

          -  Non-English speaking parents/patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Makara Cayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEEI/ Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex Ciaramella, BS</last_name>
    <phone>6175237900</phone>
    <phone_ext>34016</phone_ext>
    <email>Alex_Ciaramella@meei.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>MEEI</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Ciaramella, BS</last_name>
      <phone>617-523-7900</phone>
      <phone_ext>34016</phone_ext>
      <email>Alex_Ciaramella@meei.Harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Makara Cayer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Makara Cayer</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

